An Open-label Eslicarbazepine Acetate Long-term Safety and Tolerability Study in Children and Adolescents (4 - 17 Years)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors Sunovion Pharmaceuticals
- 21 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Jul 2017 Status changed from not yet recruiting to recruiting.
- 05 Jul 2017 Planned initiation date changed from 30 Jun 2017 to 6 Jul 2017.